Tamoxifen's Effect on Breast Tumor Growth
Author Information
Author(s): R.B. Clarke, I.J. Laidlaw, L.J. Jones, A. Howell, E. Anderson
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Does tamoxifen treatment reduce the Ki67 labelling index in human breast tumors?
Conclusion
Tamoxifen treatment significantly reduced the Ki67 labelling index in breast tumors, indicating a decrease in tumor proliferation.
Supporting Evidence
- Tamoxifen-treated patients had a median Ki67 LI of 5.6% in the first biopsy falling to 3.0% in the second biopsy.
- Placebo-treated patients had a median Ki67 LI of 5.4% in the first biopsy and 5.75% in the second.
- 69% of tamoxifen-treated tumors showed a decline in %Ki67 LI.
Takeaway
Tamoxifen helps slow down the growth of breast tumors, which is good for patients.
Methodology
Patients were randomized to receive either tamoxifen or placebo, and tumor samples were analyzed for Ki67, ER, and PR levels before and after treatment.
Limitations
The follow-up period was short, and the study did not assess long-term outcomes.
Participant Demographics
Median age was 60 years, with a range from 26 to 87 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website